Intervention

Rifabutin

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 32 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials32

Recruiting0

Common conditions16

Lead sponsors shown14

Clinical trials

32 shown

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsNCT07066722 · 2025-07-07

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsNCT05458102 · 2022-08-19

Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With TuberculosisNCT03478033 · 2018-04-15

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsNCT03149848 · 2017-06-06

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice WeeklyNCT02415985 · 2015-06-01

Drug-drug Interaction (DDI) RifabutinNCT02138084 · 2014-05-14

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIVNCT01601626 · 2013-07-13

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of MaravirocNCT01894776 · 2013-06-01

EARNEST Rifabutin Pharmacokinetics (PK) SubstudyNCT01663168 · 2011-12-01

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female VolunteersNCT01231542 · 2011-05-01

Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)NCT00925535 · 2010-05-01

Drug Interaction StudyNCT00646776 · 2008-04-01

Interaction of Buprenorphine With HIV Medications and Tuberculosis MedicationsNCT00877591 · 2008-04-01

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TBNCT00023400 · 2000-02-01

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily EfavirenzNCT00023413 · 1999-11-01

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TBNCT00023348 · 1999-07-01

TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based RegimenNCT00023361 · 1999-02-01

Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ PatientsNCT02184078 · 1998-10-01

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected PatientsNCT00001030

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected PatientsNCT00001023

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDSNCT00001047

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With TuberculosisNCT00004736

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDSNCT00001058

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative AdultsNCT00000877

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine MetabolitesNCT00000826

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDSNCT00002343

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDSNCT00001995

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or PlaceboNCT00002101

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialNCT00002267

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND StudyNCT00002080

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected PatientsNCT00002122

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialNCT00002032

Common conditions

HIV Infections22 Mycobacterium Avium-intracellulare Infection11 Tuberculosis8 Infection, Human Immunodeficiency Virus3 HIV2 HIV Infection2 Mycoses2 AIDS1 Antivirals/HIV1 Bacterial Infections1 Healthy Volunteers1 HIV-1 Infection1 Human Immunodeficiency Virus Type 1 (HIV-1) Infection1 Mycobacterium Avium Complex (MAC)1 Opioid Dependency1 Tuberculosis, Pulmonary1

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

tuberculosis8 HIV infectious disease2 AIDS1 pulmonary tuberculosis1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 7 Pharmacia 6 Centers for Disease Control and Prevention 4 ViiV Healthcare 4 Pfizer 2 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 1 Boehringer Ingelheim 1 Bristol-Myers Squibb 1 Gilead Sciences 1 Justine Boles 1 Ottawa Hospital Research Institute 1 Shanghai Public Health Clinical Center 1 The HIV Netherlands Australia Thailand Research Collaboration 1 University of California, San Francisco 1

Trial status mix

COMPLETED28

TERMINATED2

UNKNOWN2

Phase mix

PHASE112

NA7

PHASE26

PHASE35

PHASE43

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.